At Altoida, we believe that understanding your brain health should be simple and accessible. We are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.
By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores.
This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. In 2021, our device received the Breakthrough Device designation
by the FDA. Altoida's platform has demonstrated the ability to predict conversion from Mild Cognitive Impairment to Alzheimer's disease with a high degree of accuracy.